Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Vertex Pharmaceuticals (NASDAQ:VRTX) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 5 | 4 | 4 | 0 | 1 |
Last 30D | 0 | 0 | 0 | 0 | 1 |
1M Ago | 2 | 1 | 1 | 0 | 0 |
2M Ago | 2 | 1 | 2 | 0 | 0 |
3M Ago | 1 | 2 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $474.86, a high estimate of $555.00, and a low estimate of $376.00. This current average has increased by 6.67% from the previous average price target of $445.15.
An in-depth analysis of recent analyst actions unveils how financial experts perceive Vertex Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Whitney Ijem | Canaccord Genuity | Raises | Sell | $376.00 | $371.00 |
Phil Nadeau | TD Cowen | Raises | Buy | $500.00 | $450.00 |
Olivia Brayer | Cantor Fitzgerald | Raises | Overweight | $480.00 | $440.00 |
Andrew Fein | HC Wainwright & Co. | Raises | Buy | $500.00 | $462.00 |
Matthew Harrison | Morgan Stanley | Raises | Equal-Weight | $455.00 | $402.00 |
Steve Chesney | Redburn Atlantic | Announces | Buy | $545.00 | - |
Mohit Bansal | Wells Fargo | Raises | Overweight | $555.00 | $540.00 |
Jasper Hellweg | Argus Research | Raises | Buy | $550.00 | $465.00 |
Brian Abrahams | RBC Capital | Lowers | Sector Perform | $421.00 | $424.00 |
Brian Abrahams | RBC Capital | Maintains | Sector Perform | $424.00 | $424.00 |
Evan Seigerman | BMO Capital | Raises | Outperform | $500.00 | $480.00 |
Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $462.00 | $462.00 |
Brian Abrahams | RBC Capital | Raises | Sector Perform | $424.00 | $417.00 |
Christopher Raymond | Piper Sandler | Raises | Overweight | $456.00 | $450.00 |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Vertex Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Vertex Pharmaceuticals analyst ratings.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Vertex Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.3% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 40.87%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.09% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of 4.71%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.04.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VRTX